Author:
Mustanski Brian,Ryan Daniel T.,Sanchez Travis,Sineath Craig,Macapagal Kathryn,Sullivan Patrick S.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,Social Psychology
Reference39 articles.
1. US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection: US Department of Health and Human Services. 2012.
2. Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis. 2012;25:51–7.
3. CDC. Pre-exposure prophylaxis (PrEP) for HIV prevention promoting safe and effectiveness use in the United States: New tool to reduce the risk of HIV infection among gay and bisexual men. http://www.cdc.gov/hiv/prep/pdf/PrEPfactsheet.pdf (2011). Accessed 15 May 2012.
4. CDC. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR. 2005;54:1–20.
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献